PMID: 6109048Jan 3, 1981Paper

Long-term T-cell-mediated immunity to Epstein-Barr virus in renal-allograft recipients receiving cyclosporin A

Lancet
D H CrawfordA V Hoffbrand

Abstract

Peripheral-blood mononuclear cells from renal-allograft patients receiving cyclosporin A (CSA) were tested for their ability to produce T cells cytotoxic for EB-virus-infected B-cell targets in culture and compared with those from healthy seropositive subjects. Whereas in the control cultures the proliferating foci of EB-virus-transformed B cells regressed after 2 weeks, no such regression was seen in cultures from CSA-treated patients. These results indicate that patients receiving CSA cannot mount a cytotoxic response to EB-virus-infected B cells in vitro. It is suggested that suppression of memory-T-cell proliferation contributes to the high incidence of lymphomas in CSA-treated renal-allograft recipients.

References

Apr 1, 1975·Proceedings of the National Academy of Sciences of the United States of America·E Svedmyr, M Jondal
Jan 1, 1977·Annual Review of Microbiology·M A Epstein, B G Achong
May 15, 1979·International Journal of Cancer. Journal International Du Cancer·A B RickinsonJ H Pope
May 1, 1973·International Journal of Cancer. Journal International Du Cancer·B M Reedman, G Klein
Feb 1, 1972·Proceedings of the National Academy of Sciences of the United States of America·G MillerM Lipman
Aug 23, 1980·Lancet·A G Bird, S M McLachlan
Aug 7, 1980·The New England Journal of Medicine·R WarnkeR Levy

❮ Previous
Next ❯

Citations

Jan 1, 1996·Transplant International : Official Journal of the European Society for Organ Transplantation·L M BarkholtA Lindé
Dec 31, 1998·Springer Seminars in Immunopathology·C L Davis
Jan 1, 1983·Medical Microbiology and Immunology·M von Knebel DoeberitzH zur Hausen
Apr 1, 1990·Irish Journal of Medical Science·M J Turner
Feb 21, 1981·Lancet·R G Gibson, S L Gibson
Feb 28, 1987·Lancet·J W GratamaJ M Vossen
Oct 1, 1989·Journal of Autoimmunity·I T Cockburn, P Krupp
Apr 21, 2001·Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences·G W Bornkamm, W Hammerschmidt
Feb 1, 1992·Australian and New Zealand Journal of Medicine·K NgE Marshall
Aug 1, 1984·The British Journal of Venereal Diseases·D H CrawfordD W Wara
May 1, 1981·Immunology Today·G G Klaus
Apr 1, 1982·Current Problems in Cancer·I Penn
Nov 14, 2006·Pediatric Transplantation·Françoise Smets
Mar 22, 1984·Proceedings of the Royal Society of London. Series B, Containing Papers of a Biological Character·M A Epstein
Jan 1, 1984·Annals of the New York Academy of Sciences·M A Epstein
Jan 1, 1984·Annals of the New York Academy of Sciences·I WellerM W Adler
Jan 1, 1987·Critical Reviews in Clinical Laboratory Sciences·W J RichtsmeierE M Mazur
Sep 1, 1990·The Journal of Laryngology and Otology·J W FairleyM H Yacoub
May 1, 1992·Japanese Journal of Cancer Research : Gann·S TamuraO Yoshie
Jan 15, 1985·International Journal of Cancer. Journal International Du Cancer·Q Y YaoM A Epstein
Dec 1, 1999·Reviews in Medical Virology·I Johannessen, D H Crawford
Aug 1, 1987·Immunology and Cell Biology·L K Ashman
May 1, 1990·Journal of Clinical Microbiology·C A CrouseS S Atherton
Mar 29, 2001·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·S R SmithA Greenberg

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.